Citations

Mayo Clinic

Clear

1523 citation(s) found for "Ma, Rachel".

Patient Length of Stay Under the Two-Midnight Rule: Assessing the Accuracy of Providers’ Predictions
Lindor, Rachel A. , Bellolio, Fernanda , Madsen, Bo E., Newman, James S. , Lohse, Christine M. , Jeffery, Molly M. , Boon, Ashton L., Goyal, Deepi G. , Sadosty, Annie T., Jeffery, Molly Moore , Bellolio, M Fernanda , Lindor, Rachel A

Journal of Healthcare Management | July 8, 2020 | Volume: 65 | Issue: 4 | Pages: 273-283

10.1097/jhm-d-18-00167 | PMID 32639321 Get It

EXECUTIVE SUMMARY We sought to determine emergency medicine physicians’ accuracy in designating patients’ disposition status as “inpatient” or “observation” at the time of hospital admission in the context of Medicare’s Two-Midnight rule and to identify characteristics that may improve the providers’ predictions. We conducted a 90-day observational study of emergency department (ED) admissions involving adults aged 65 years and older and assessed the accuracy of physicians’ disposition decisions. Logistic regression models were fit to explore associations and predictors of disposition. A total of 2,257 patients 65 and older were admitted through the ED. The overall error rate in physician designation of observation or inpatient was 36%. Diagnoses most strongly associated with stays lasting less than two midnights included diverticulitis, syncope, and nonspecific chest pain. Diagnoses most strongly associated with stays lasting two or more midnights included orthopedic fractures, biliary tract disease, and back pain. ED physicians inaccurately predicted patient length of stay in more than one third of all patients. Under the Two-Midnight rule, these inaccurate predictions place hospitals at risk of underpayment and patients at risk of significant financial liability. Further work is needed to increase providers’ awareness of the financial repercussions of their admission designations and to identify interventions that can improve prediction accuracy.
Imaging-Based Tissue Heterogeneity to Predict Disease Extent in IPF
John, Joyce , Bartholmai, B., Levin, David L. , King, C., Wilsher, Margaret , Milne, David , Kenneth, Wang Qing, Clark, Alys Rachel , Kumar, Haribalan , Tawhai, Merryn Howatson

A23. ILD PROGNOSIS AND BIOMARKERS I | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A1082-A1082

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1082 Get It

Sialic acid–bearing paraproteins are implicated in heparin-like coagulopathy in patients with myeloma
Seheult, Jansen N. , Ladwig, Paula M. , Tange, Julie I, Leger, Rachel, Kohlhagen, Mindy , Ashrani, Aneel A. , Murray, David , Saadalla, Abdulrahman , Ladwig, Paula, Tange, Julie, Ashrani, Aneel, Seheult, Jansen N

Blood | June 27, 2020 | Volume: 136 | Issue: 17 | Pages: 1988-1992

10.1182/blood.2020005604 | PMID 32589705 Get It

Genome-Wide Gene–Diabetes and Gene–Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia
Tang, Hongwei, Jiang, Lai , Arslan, Alan A. , Bracci, Paige M. , Brennan, Paul , Canzian, Federico , Du, Mengmeng , Gallinger, Steven , Goodman, Phyllis J. , Visvanathan, Kala , Andreotti, Gabriella , Babić, Ana , Berndt, Sonja I. , Bueno‐de‐Mesquita, Bas , Buring, Julie E. , Campa, Daniele , Childs, Erica J., Fuchs, Charles S. , Gaziano, J. Michael , Hartge, Patricia, Hassam, Manal H., Holly, Elizabeth A. , Hoover, Robert N. , Hung, Rayjean J. , Kurtz, Robert C. , Lee, I-Min, Ng, Kimmie , Oberg, Ann L. , Peters, Ulrike , Porta, Miquel , Rabe, Kari G. , Rothman, Nathaniel , Scélo, Ghislaine , Sesso, Howard D. , Thompson, Ian M. , Tjønneland, Anne , Trichopoulou, Antonia , Wactawski‐Wende, Jean , Wentzensen, Nicolas , Zeleniuch‐Jacquotte, Anne , Jacobs, Eric J. , Petersen, Gloria M. , Wolpin, Brian M. , Chatterjee, Nilanjan , Li, Donghui , Arslan, Alan A , Brennan, Paul , Canzian, Federico , Bamlet, William R , Blackford, Amanda , Duell, Eric J , Hung, Rayjean J , Malats, Nuria , Milne, Roger L , Oberg, Ann L , Orlow, Irene , Sesso, Howard D , Tjønneland, Anne , Wactawski-Wende, Jean , Yu, Herbert , Amundadottir, Laufey , Klein, Alison P , Li, Donghui , Chaffee, Kari G. , Visvanathan, Kala , Porta, Miquel , Thompson, Ian M , Zeleniuch-Jacquotte, Anne , Stolzenberg‐Solomon, Rachael Z. , Freeman, Laura E. Beane , Giles, Graham G. , Kooperberg, Charles , Marchand, Loı̈c Le , Neale, Rachel Ε. , Shu, Xiao‐Ou , White, Emily , Zheng, Wei , Albanes, Demetrius , Bamlet, William R. , Chanock, Stephen Jacob , Duell, Eric J. , Goggins, Michael , Malats, Núria , Milne, Roger L. , Orlow, Irene , Rothman, Nathaniel , Silverman, Debra T. , Wilkens, Lynne R. , Yu, Kai , Ámundadóttir, Laufey T. , Risch, Harvey A. , Klein, Alison P. , Kraft, Peter , Wei, Peng

Cancer Epidemiology, Biomarkers & Prevention | June 16, 2020 | Volume: 29 | Issue: 9 | Pages: 1784-1791

10.1158/1055-9965.epi-20-0275 | PMID 32546605 Get It

Abstract Background: Obesity and diabetes are major modifiable risk factors for pancreatic cancer. Interactions between genetic variants and diabetes/obesity have not previously been comprehensively investigated in pancreatic cancer at the genome-wide level. Methods: We conducted a gene–environment interaction (GxE) analysis including 8,255 cases and 11,900 controls from four pancreatic cancer genome-wide association study (GWAS) datasets (Pancreatic Cancer Cohort Consortium I–III and Pancreatic Cancer Case Control Consortium). Obesity (body mass index ≥30 kg/m2) and diabetes (duration ≥3 years) were the environmental variables of interest. Approximately 870,000 SNPs (minor allele frequency ≥0.005, genotyped in at least one dataset) were analyzed. Case–control (CC), case-only (CO), and joint-effect test methods were used for SNP-level GxE analysis. As a complementary approach, gene-based GxE analysis was also performed. Age, sex, study site, and principal components accounting for population substructure were included as covariates. Meta-analysis was applied to combine individual GWAS summary statistics. Results: No genome-wide significant interactions (departures from a log-additive odds model) with diabetes or obesity were detected at the SNP level by the CC or CO approaches. The joint-effect test detected numerous genome-wide significant GxE signals in the GWAS main effects top hit regions, but the significance diminished after adjusting for the GWAS top hits. In the gene-based analysis, a significant interaction of diabetes with variants in the FAM63A (family with sequence similarity 63 member A) gene (significance threshold P < 1.25 × 10−6) was observed in the meta-analysis (PGxE = 1.2 ×10−6, PJoint = 4.2 ×10−7). Conclusions: This analysis did not find significant GxE interactions at the SNP level but found one significant interaction with diabetes at the gene level. A larger sample size might unveil additional genetic factors via GxE scans. Impact: This study may contribute to discovering the mechanism of diabetes-associated pancreatic cancer.
Guidance for Rebooting Electrophysiology Through the COVID-19 Pandemic From the Heart Rhythm Society and the American Heart Association Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology
Lakkireddy, Dhanunjaya , Chung, Mina K. , Deering, Thomas F. , Gopinathannair, Rakesh , Epstein, Laurence M. , Harding, Clifford V. , Hurwitz, Jodie L. , Jeffery, Courtney, Krahn, Andrew D. , Lampert, Rachel , Mansour, Moussa , Natale, Andrea , Seiler, Amber , Shah, Maully J. , Wang, Paul J. , Russo, Andrea M. , Kusumoto, Fred M, Krahn, Andrew D , Natale, Andrea , Gopinathannair, Rakesh , Epstein, Laurence M , Albert, Christine M. , Kusumoto, Fred , Patton, Kristen K.

Circulation: Arrhythmia and Electrophysiology | June 12, 2020 | Volume: 13 | Issue: 7 | Pages: No page available

10.1161/circep.120.008999 | PMID 32530306 Get It

Coronavirus disease 2019 (COVID-19) has presented substantial challenges to patient care and impacted healthcare delivery, including cardiac electrophysiology practice throughout the globe. Based upon the undetermined course and regional variability of the pandemic, there is uncertainty as to how and when to resume and deliver electrophysiology services for patients with arrhythmia. This joint document from representatives of the Heart Rhythm Society, American Heart Association, and American College of Cardiology seeks to provide guidance for clinicians and institutions reestablishing safe electrophysiological care. To achieve this aim, we address regional and local COVID-19 disease status, the role of viral screening and serological testing, return-to-work considerations for exposed or infected health care workers, risk stratification and management strategies based on COVID-19 disease burden, institutional preparedness for resumption of elective procedures, patient preparation and communication, prioritization of procedures, and development of outpatient and periprocedural care pathways.
Endocrine Conditions and COVID-19
Shekhar, Skand , Wurth, Rachel , Kamilaris, Crystal , Eisenhofer, Graeme , Barrera, Francisco J. , Hajdenberg, Michelle , Tonleu, Joselyne, Schiffrin, Ernesto L. , Porter, Forbes D. , Hannah‐Shmouni, Fady , Schiffrin, Ernesto L , Hannah-Shmouni, Fady , Tonleu, Joselyne Tessa , Hall, Janet Elizabeth , Stratakis, Constantine A.

Hormone and Metabolic Research | June 8, 2020 | Volume: 52 | Issue: 07 | Pages: 471-484

10.1055/a-1172-1352 | PMID 32512611 Get It

AbstractCOVID-19 was declared a global pandemic by the WHO and has affected millions of patients around the world. COVID-19 disproportionately affects persons with endocrine conditions, thus putting them at an increased risk for severe disease. We discuss the mechanisms that place persons with endocrine conditions at an additional risk for severe COVID-19 and review the evidence. We also suggest precautions and management of endocrine conditions in the setting of global curfews being imposed and offer practical tips for uninterrupted endocrine care.
Medication-Assisted Treatment for Opioid Use Disorder in a Rural Family Medicine Practice
Deyo-Svendsen, Mark , Svendsen, Matthew Cabrera, Hodges, Andrea, Oldfather, Rachel Z., Mansukhani, Meghna P. , Cabrera Svendsen, Matthew, Walker, James, Mansukhani, Meghna P , Deyo-Svendsen, Mark E , Walker, James E.

Journal of Primary Care & Community Health | June 6, 2020 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/2150132720931720 | PMID 32507023 Get It

Opioid use disorder (OUD) is a cause of significant morbidity and mortality in the United States. Although efforts are being made to limit access to prescription opioids, the use of heroin and synthetic opioids as well as death due to opioid overdose has increased. Medication-assisted treatment (MAT) is the pairing of psychosocial intervention with a Food and Drug Administration (FDA)–approved medication (methadone, buprenorphine plus naltrexone) to treat OUD. MAT has resulted in reductions in overdose deaths, criminal activity, and infectious disease transmission. Access to MAT in rural areas is limited by shortages of addiction medicine-trained providers, lack of access to comprehensive addiction programs, transportation, and cost-related issues. Rural physicians express concern about lack of mentorship and drug diversion as reasons to avoid MAT. The prescribing of MAT with buprenorphine requires a Drug Enforcement Agency (DEA) waiver that can easily be obtained by Family Medicine providers. MAT can be incorporated into the outpatient practice, where patient follow-up rates and number needed to treat to effect change are similar to that of other chronic medical conditions. We describe a case of opioid overdose and a suggested protocol for the induction of MAT with buprenorphine/naloxone (Suboxone) for OUD in a rural family medicine outpatient practice. Treatment access is facilitated by utilizing the protocol, allowing office staff work to the extent allowed by their licensure, promoting teamwork and minimizing physician time commitment. We conclude that improved access to MAT can be accomplished in a rural family medicine outpatient clinic by staff that support and mentor one another through use of a MAT protocol.
Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Hoppe, Richard T. , Advani, Ranjana H. , Ambinder, Richard F. , Armand, Philippe , Bello, Celeste, Benitez, Cecil M. , Bierman, Philip J., Boughan, Kirsten M, Dabaja, Bouthaina S. , Hernandez‐Ilizaliturri, Francisco J. , Herrera, Alex F. , Hochberg, Ephraim P. , Johnston, Patrick B. , Kaminski, Mark , Kenkre, Vaishalee P. , Khan, Nadia , Lynch, Ryan C. , Maddocks, Kami J. , McKinney, Matthew , Metzger, Monika L. , Morgan, David , Mulroney, Carolyn , Rabinovitch, Rachel , Rosenspire, Karen C., Seropian, Stuart , Burns, Jennifer L. , Ogba, Ndiya , Advani, Ranjana H , Khan, Nadia , Hoppe, Richard T , Ambinder, Richard F , Ai, Weiyun Z. , Gordon, Leo I. , Huang, Jiayi , McConathy, Jonathan , Tao, Randa , Winter, Jane N. , Yahalom, Joachim

Journal of the National Comprehensive Cancer Network | June 5, 2020 | Volume: 18 | Issue: 6 | Pages: 755-781

10.6004/jnccn.2020.0026 | PMID 32502987 Get It

The NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma (HL) provide recommendations for the management of adult patients with HL. The NCCN panel meets at least annually to review comments from reviewers within their institutions, examine relevant data, and reevaluate and update their recommendations. Current management of classic HL involves initial treatment with chemotherapy alone or combined modality therapy followed by restaging with PET/CT to assess treatment response. Overall, the introduction of less toxic and more effective regimens has significantly advanced HL cure rates. This portion of the NCCN Guidelines focuses on the management of classic HL.
Inverted Papilloma of the Orbit and Nasolacrimal System
Wang, Jessie , Ford, Joshua , Esmaeli, Bita , Langer, Paul D. , Esmaili, Neda, Griepentrog, Gregory J. , Couch, Steven M., Nguyen, John , Gold, Katherine G., Duerksen, Kathleen M., Burkat, Cat N., Hartstein, Morris E., Gandhi, Parag, Sobel, Rachel K. , Moon, Jee‐Young , Barmettler, Anne

Ophthalmic Plastic & Reconstructive Surgery | June 5, 2020 | Volume: 37 | Issue: 2 | Pages: 161-167

10.1097/iop.0000000000001719 | PMID 32501879 Get It

Purpose: Periocular inverted papilloma (IP) is a rare, locally aggressive tumor with a propensity for recurrence and malignant transformation. Historically treated via wide excision, this study examines the characteristics and management of periocular IP, comparing those confined to the nasolacrimal system with those invading the orbit. Methods: An Institutional Review Board-approved, Health Insurance Portability and Accountability Act-compliant retrospective, comparative case series was conducted in patients with IP of the orbit or nasolacrimal system across 15 clinical sites. Results: Of 25 patients, 22 met inclusion criteria with 9 limited to the nasolacrimal system and 13 invading the orbit. Mean age was 60.4 years, 55% were women, all were unilateral. Mean follow-up was 48 months. Rates of smoking, dust and/or aerosol exposure, human papillomavirus (HPV) status, and inflammatory polyps were elevated compared to rates in the general population (45%, 18%, 18%, and 14%, respectively). Bony erosion on computed tomography scans was statistically significantly associated with orbit-invading IP (p = 0.002). Treatment involved all confined IP undergoing surgery alone while 39% of orbit-invading IP also received radiation therapy and/or chemotherapy (p = 0.054). Orbit-invading IP was more likely to be excised with wide margins than IP confined to the nasolacrimal system (85% vs. 22%, p = 0.007). Overall rates of malignancy, recurrence, and patient mortality from IP were found to be 27%, 23%, and 9%, respectively. Conclusions: IP invading the orbit typically requires aggressive therapy, while IP confined to the nasolacrimal system may be treated more conservatively. Using risk factors, characteristics, and outcomes, a treatment algorithm was created to guide management.
NCCN Guidelines Insights: Cervical Cancer, Version 1.2020
Abu‐Rustum, Nadeem R. , Yashar, Catheryn M. , Bean, Sarah , Bradley, Kristin , Campos, Susana M. , Chon, Hye Sook, Damast, Shari , Fisher, Christine M. , Frederick, Peter J., Gaffney, David K. , Giuntoli, Robert , Han, Ernest , Huh, Warner K. , Lurain, John R., Mariani, Andrea , Nagel, Christa , Nekhlyudov, Larissa , Fader, Amanda N. , Remmenga, Steven W., Reynolds, R. Kevin, Sisodia, Rachel , Tillmanns, Todd , Ueda, Stefanie , Urban, Renata R. , Wyse, Emily , McMillian, Nicole R., Motter, Angela D., Chu, Christina , Cohn, David E. , Crispens, Marta Ann , Mutch, David G.

Journal of the National Comprehensive Cancer Network | June 5, 2020 | Volume: 18 | Issue: 6 | Pages: 660-666

10.6004/jnccn.2020.0027 | PMID 32502976 Get It

The NCCN Guidelines for Cervical Cancer provide recommendations for diagnostic workup, staging, and treatment of patients with the disease. These NCCN Guidelines Insights focus on recent updates to the guidelines, including changes to first- and second-line systemic therapy recommendations for patients with recurrent or metastatic disease, and emerging evidence on a new histopathologic classification system for HPV-related endocervical adenocarcinoma.